Dubai, UAE, 5 February 2024 – MGI, a company dedicated to developing core tools and technologies to lead life science innovation, today announced a collaboration with Prepaire Labs at MEDLAB Middle East 2024 to further advance precision medicine. The collaboration includes MGI’s first corporate order of the revolutionary DNBSEQ-T20×2 (“T20”) ultra-high-throughput sequencer in the Middle East, as well as the first application of MGI’s sequencing technology in drug discovery in the region.
“We are thrilled to work with Prepaire Labs to harness the T20’s ultra-high throughput and exceptional cost efficiency to better understand and treat disease at a personalised level,” said Roy Tan, General Manager of MGI Asia Pacific. “This partnership reflects our commitment to expanding global access to genomics through high-quality, cutting-edge platforms.”
Powered by MGI’s proprietary DNBSEQ technology, the T20 is a fully automated genetic sequencer that has achieved major technological breakthroughs, significantly reducing genome sequencing costs to below USD 100 per genome. Designed to address the most demanding sequencing scenarios, it supports a wide range of high-throughput applications in research and clinical settings, including whole-genome sequencing (WGS), whole-genome bisulphite sequencing (WGBS), stLFR, single-cell sequencing, Stereo-seq, and more.
MGI and Prepaire Labs will collaborate on:
- Developing assays for whole-genome sequencing
- Building a fully automated smart laboratory
- Innovating sequencing methods for complex genome analysis
- Co-marketing initiatives to strengthen scientific collaboration
Founded in 2020, Prepaire Labs is an Abu Dhabi-based company focused on transforming drug discovery and precision medicine. As part of its initiative to establish an advanced semi-autonomous BSL3 laboratory in the UAE, the addition of the T20 will enable Prepaire Labs to deliver flexible, high-capacity genome sequencing services critical to the Biotune platform’s cost-effective, personalised healthcare solutions.
“Our collaboration with MGI supports our mission to bring advanced genomic sequencing closer to real-world clinical applications,” said Carl Freer, Founder of Prepaire Labs. “Together, we are building on recent progress to further empower researchers and healthcare providers.”
MGI’s DNBSEQ-T20×2, along with other technologies including the ZOID-ILR laboratory robot, DNBSEQ™ sequencing platforms, automated sample preparation systems, and ultra-low-temperature biorepository solutions, will be on display at MEDLAB Middle East 2024. Visitors are welcome at MGI’s booth #Z4.H10 at the Dubai World Trade Centre from 5 to 8 February.
About Prepaire Labs
Prepaire Labs is a healthcare technology company dedicated to advancing drug discovery and precision medicine. By integrating deep learning with biology, the company develops predictive models based on genetic, phenotypic, and clinical data to uncover the underlying architecture of disease. Prepaire Labs utilises patient-derived induced pluripotent stem cells (iPSCs), genome editing, high-content cellular phenotyping, and machine learning to create in vitro disease models that enhance the predictability of human clinical outcomes. A state-of-the-art BSL3 laboratory is scheduled to open in May 2024 at Masdar City, Abu Dhabi, serving as a fully automated Lab-as-a-Service (LaaS) hub.
About Biotune
The Biotune digital twin represents a new convergence of healthcare and technology. More than a visual avatar, it is a dynamic model incorporating genetic data, medical history, and real-time biometrics. Healthcare professionals can use this continuously evolving dataset for diagnosis and treatment planning, enabling a level of precision and personalisation that was previously unattainable.
